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AbstrACt
Introduction Creatine supplementation has 
consistently been demonstrated to augment adaptations 
in body composition, muscle strength and physical 
function in a variety of apparently healthy older 
adults and clinical populations. The effects of creatine 
supplementation and resistance training in individuals 
with cancer have yet to be investigated. This study aims 
to examine the effects of creatine supplementation 
in conjunction with resistance training on body 
composition, muscle strength and physical function 
in prostate cancer patients undergoing androgen 
deprivation therapy.
Methods and analysis This is a randomised, double-
blind, placebo-controlled trial designed to examine 
the effects of creatine supplementation in addition 
to resistance training in patients with prostate 
cancer receiving androgen deprivation therapy. Both 
supplement and placebo groups will receive a 12-week 
supervised exercise programme comprising resistance 
training undertaken three times per week. The primary 
endpoint (fat-free mass) and secondary endpoints (fat 
mass, per cent body fat, physical fitness, quality of life 
and blood biomarkers) will be assessed at baseline and 
immediately following the intervention.
Ethics and dissemination The Human Research Ethics 
Committee of Edith Cowan University approved this 
study (ID: 22243 FAIRMAN). If the results of this trial 
demonstrate that creatine supplementation can augment 
beneficial adaptations of body composition, physical 
function and/or psychosocial outcomes to resistance 
training, this study will provide effect sizes that will 
inform the design of subsequent definitive randomised 
controlled trials. The results of this study will be 
published in peer-reviewed journals and presented at 
various national and international conferences.
trial registration number ACTRN12619000099123
IntroduCtIon
Androgen deprivation therapy (ADT) is 
frequently incorporated into the manage-
ment of men with localised and advanced 
prostate cancer (PCa).1 Unfortunately, the 
catabolic effects of ADT result in loss of fat-free 
mass (FFM), increased fat mass, reduced 
muscle strength and lower bone mineral 
density (BMD).2–5 In turn, these adverse 
effects of ADT are linked with functional 
decline (ie, reduced walking speed, ability to 
rise from a chair or climb stairs, etc), frailty, 
and increased risk for cardiovascular disease, 
metabolic syndrome and osteoporosis.6 Thus, 
patients with PCa endure long and lingering 
strengths and limitations of this study
 ► This is the first trial designed to examine the effects 
of creatine supplementation and resistance train-
ing on body composition in patients with prostate 
cancer, addressing a critical area of concern in this 
population.
 ► Both groups receive an exercise intervention which 
may enhance recruitment affording all patients the 
benefits of exercise and negates questions sur-
rounding attention control.
 ► The study is limited to men with prostate cancer on 
androgen deprivation therapy and results may not 
be generalised to other populations.
 ► The inclusion of dietary analysis at baseline, 6-week 
midpoint and 12-week follow-up will offer additional 
insight into dietary habits of participants that may 
influence muscle hypertrophy (ie, protein intake).
 ► The lack of follow-up assessments limits informa-
tion on the sustainability of benefit.
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impacts on physical function, health status and quality of 
life (QOL) that accompany ADT as a ‘trade-off’ for more 
effective cancer control and extended longevity.
Resistance training has gained increasing attention in 
the recent years, with the results from numerous studies 
supporting resistance training as a promising strategy to 
counteract declining body composition, BMD and phys-
ical function mediated by ADT.7–11 Nevertheless, there 
remains a pronounced exacerbation of normal ageing 
(decline in lean body mass, muscular strength and endur-
ance) as a result of ADT, resulting in an accelerated trajec-
tory towards a ‘disability’ condition (ie, the difficulty or 
reduced ability to perform activities essential to indepen-
dent living).12 Consequently, there is an urgent need for 
strategies to augment resistance training adaptations and 
further target the worsening of body composition, muscle 
strength and physical function in this population.6 13–15
More recently, there has been greater emphasis on the 
need for multimodal strategies combining exercise and 
dietary/supplementation interventions to more aggres-
sively target.
FFM in patients with cancer.16 Creatine (Cr) is one of the 
most widely studied supplements (SUPPs), with research 
consistently demonstrating greater improvements in 
FFM, strength and physical function when combined with 
resistance training, compared with that achieved with 
resistance training alone.17–22 Further, emerging research 
has demonstrated the efficacy of Cr supplementation for 
improving FFM, BMD, muscle strength and physical func-
tion in older adults or clinical populations with similar 
muscle wasting characteristics to cancer, such as muscular 
dystrophy and HIV.23–30
Cr supplementation increases intramuscular stores of 
phosphocreatine (PCr), a high-energy phosphate that 
plays a critical role in energy provision during exercise.31 
It is hypothesised that Cr uptake by skeletal muscle is 
modulated by muscle activity.32 Importantly, the ability to 
sustain exercise effort is dependent on PCr availability, 
which diminishes with intense exercise. Increases in 
PCr stores may contribute to an accelerated resynthesis 
of adenosine triphosphate (ATP) during exercise.19 20 
Consequently, the ergogenic effects of Cr supplementa-
tion are likely a result from an increase in overall training 
volume and/or quality,19 20 due to increases in intramus-
cular PCr stores32 33 enhancing exercise capacity. Taken 
collectively, there is the potential that Cr supplementa-
tion may enhance the quality and/or quantity of resis-
tance training in patients with PCa, leading to augmented 
adaptations in FFM, muscle strength and/or function.16 
Given the overwhelming evidence of Cr supplementation 
in other populations, there is large therapeutic potential 
for its use in patients with PCa.16
The primary aim of this study is to examine the effects 
of Cr supplementation in conjunction with resistance 
training on body composition, muscle strength and phys-
ical function in patients with PCa undergoing ADT. It is 
hypothesised that resistance training plus Cr will lead to 
greater improvements in FFM, muscle strength, QOL and 
physical function than that of resistance training alone. 
The results of this study will provide insights into the 
effects of Cr supplementation as a potential low-cost ther-
apeutic agent to target FFM in men with PCa receiving 
ADT.
MEthods
study design
This is a randomised, double-blind, placebo (PLA)-con-
trolled trial designed to examine the effects of Cr 
supplementation in addition to resistance training 
in patients with PCa receiving ADT. Both SUPP and 
PLA groups will receive a 12-week supervised exercise 
programme comprising of resistance training under-
taken three times per week. In addition, participants in 
the SUPP group will receive a daily dose of Cr: 20 g/
day during a loading phase of 5 days (the last 5 days of 
the familiarisation period, described in detail later) and 
then 5 g/day thereafter for the duration of the 12-week 
exercise intervention. Participants in the PLA group 
will follow the same dosing protocol with dextrose. 
There will be a 2-week testing/familiarisation period 
(detailed further in this manuscript) prior to the begin-
ning of the intervention, with post-testing occurring in 
the 2 weeks following the intervention. Consequently, 
the total length of the study is approximately 16 weeks. 
An overview of the study design and participant flow is 
depicted in figure 1.
Participants
Fifty-six men (n=56) with localised or locally advanced 
PCa, who are currently on ADT (and expected to 
remain on ADT for at least 4 months postrecruitment), 
will be eligible to enrol in this study. Participants will 
be excluded if they have any visceral or bone metas-
tases (ie, advanced or castrate-resistant PCa); are being 
treated for any secondary or other cancers or are 
currently participating in regular structured resistance 
training (>2 days/week for 6 months) or are receiving 
medications known to alter body composition (ie, corti-
costeroids, metformin, etc). Individuals who are partic-
ipating in regular structured aerobic training (>2 days 
a week) will not be excluded. Baseline activity will be 
recorded and participants enrolled in the study will 
be asked not to modify outside activity. Additionally, 
participants will be excluded if they have taken Cr in 
the previous 6 months.
recruitment
Participants will be recruited through a variety of avenues 
in Perth, Western Australia. Primarily, participants will 
be approached by their attending specialist, who will 
discuss details of the trial and provide individuals with a 
study information sheet and referral to the study coordi-
nator, who will verify eligibility by a telephone conversa-
tion. Additionally, flyers will be posted throughout local 
medical clinics in the Perth area. All participants must 
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Figure 1 Overview of study design.
receive physician clearance and provide informed consent 
prior to participation in the trial. Proposed participant 
flow throughout the study is presented in figure 2.
Measurements
Baseline and follow-up assessments will be undertaken 
within 2 weeks of the participant beginning or completing 
the intervention, respectively. An overview of assessments 
and timeline of study activities is outlined in table 1.
randomisation
Following baseline assessments (ie, on day 4 of familia-
risation phase, following completion of strength and 
physical function testing), consenting participants will 
be randomised in a ratio of 1:1 to either SUPP or PLA 
using computer-generated random assignment by a 
member of the study team with no contact with partici-
pants. Participants will be stratified according to time on 
ADT (≤6 and >6 months), age (≤65 and >65 years) and 
randomly assigned to one of the two groups. All partici-
pants and members of the study team will be blinded to 
group allocation.
Primary endpoint
Fat free mass
Whole body FFM and appendicular (lower and upper 
limb) skeletal muscle mass will be assessed using dual-en-
ergy X-ray absorptiometry (Horizon A, Hologic, Massa-
chusetts, USA) in accordance with Hart et al.34 Participants 
will be asked to avoid strenuous exercise for 24 hours 
prior to testing. Further, they will be instructed to avoid 
the consumption of food and water 4 hours and 1 hour 
prior to testing, respectively.
Secondary endpoints
Muscle strength
Dynamic muscle strength will be assessed using one-rep-
etition maximum (1RM) tests for chest press, seated row 
and leg press exercises.7 15 1RM tests are the standard 
by which muscular strength is evaluated and have been 
used in prior investigations in individuals with cancer.7 15 
Participants will be asked to perform a general warm-
up, followed by two exercise-specific warm-up sets (4–6 
repetitions), separated by 90–180 s. Participants will then 
be asked to complete a maximal attempt (the maximal 
amount of weight an individual can lift with proper tech-
nique through a full range of motion). Several maximal 
lifts will be attempted (separated by 3–5 min) until the 
participant reaches a weight that cannot be lifted using 
proper technique. Efforts will be made to ensure a 1RM is 
reached in as few attempts as possible.
QOL and fatigue
Health-related QOL for general health, pain, vitality, 
social functioning, emotional role and mental health will 
be assessed using the Medical Outcomes Short Form 36 
V.2.35 Cancer-specific QOL indices will be measured using 
the European Organisation for Research and Treatment 
of Cancer (EORTC) Quality of Life Questionnaire-C30 
and EORTC PR-25,36 37 assessing physical, emotional, 
cognitive and sexual functioning, along with PCa-specific 
symptoms. Cancer-related fatigue will be assessed using 
the Functional Assessment of Chronic Illness Therapy-Fa-
tigue questionnaire.38
Physical fitness
A battery of standard tests will be used to assess phys-
ical function, including the 400 m walk test; the timed 
up-and-go test, and repeated chair rise test to assess phys-
ical function.7 15 The 400 m walk test will be completed in a 
corridor/hallway with two cones spaced 20 m apart. Indi-
viduals will be asked to walk around the cones as quickly as 
possible, completing a total of 10 laps, with the total time 
to completion recorded. The timed up-and-go test will be 
completed with a chair and a cone placed 3 m away. Indi-
viduals will be instructed to begin the test seated in the 
chair, then instructed to get up, walk around the cone 
and sit back down, with the total time for 1 lap recorded. 
For the timed-up-and-go test and repeated chair rise, the 
chair will be placed against a wall to ensure the safety of 
participants. The repeated chair rise will be completed 
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Figure 2 CONSORT diagram. CONSORT, Consolidated Standards of Reporting Trials.
by having the patient sit in a chair, and asked to rise to a 
full standing position, sit back down and repeat five times 
as quickly as possible, with the total time recorded as the 
performance measure.
Other measures
Medical history
Information pertaining to cancer-specific (treatment 
history, time on treatment, stage of cancer and time since 
diagnosis, etc) and general medical history (comorbidi-
ties, lifestyle, concomitant medications and other chronic 
diseases, etc) will be obtained via questionnaires prior to 
baseline testing, and will be actively monitored through 
out the trial to capture any changes.
Diet recall
Additionally, participants will be asked to complete a 
3-day food record of the days preceding baseline testing. 
They will be asked to replicate this diet for post-testing. 
Further, a 3-day diet recall will be completed at midpoint 
to gain further information about dietary changes that 
may occur throughout the study.
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Table 1 Overview of testing and timeline of study activities
Time point Week 1 Week 2 Week 15 Week 16
Informed consent x
Medical history and demographics x
3-day food recall x x
Body composition (DXA) x x
1RM, (leg press, chest press, seated row)   x x
Physical function (400 m walk; timed up-and-go test; repeated 
chair rise)
  x x
Quality of life (SF-36, EORTC-QLQ-C30; EORTC-PR25; FACIT-F) x x
Gastrointestinal questionnaire x x x
Blood draw x x
DXA, dual-energy X-ray absorptiometry; EORTC-PR25, European Organisation for Research and Treatment of Cancer Prostate Cancer 
Module; EORTC-QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; FACIT-F, Functional 
Assessment of Chronic Illness Therapy-Fatigue; 1RM, one repetition maximum; SF-36, Short Form 36.
Anthropometrics
Height will be recorded to the nearest 1 cm using a wall-
mounted stadiometer (Model 222, Seca, Hamburg, DE), 
with body mass recorded to the nearest 0.1 kg using an 
electronic scale (AE Adams CPW Plus-200, Adam Equip-
ment, Connecticut, USA).
Adverse effects
In order to examine any potential side effects of supple-
mentation in this population, fasted blood samples will 
be collected and analysed commercially by an accredited 
National Association of Testing Authorities laboratory 
(Australian Clinical Labs, Perth, Australia) for creatinine 
at baseline and follow-up. Additionally, participants will 
be asked to complete questionnaires related to gastroin-
testinal distress (nausea, bloating and upset stomach, etc) 
and muscle cramping.19 Accredited exercise physiologists 
(AEPs, Exercise and Sport Science Australia) will super-
vise the exercise sessions, ensuring correct technique and 
appropriate progression, minimising the risk of adverse 
events. Consequently, a data monitoring and safety 
committee has not been appointed. However, participants 
will be consistently monitored for any adverse effects, and 
other disease-related or exercise-related adverse events 
using adverse event logs across each patient’s on-trial 
period, throughout the testing and training sessions. 
Adverse events will be documented in accordance with 
Exercise Medicine Research Institute (EMRI) standards 
and reported to the HREC. Additionally, the participant 
will be referred to their general practitioner or specialist, 
as appropriate for a medical assessment of any adverse 
event. Participants are free to withdraw from the study at 
any time.
Familiarisation and baseline testing
All participants enrolled in the study will undergo a 2-week 
familiarisation/testing period, where they will complete 
baseline testing, begin the supplementation protocol 
and receive instruction on safe and appropriate exercise 
technique. Specifically, participants will undergo baseline 
body composition testing on day 1. Following 2 days of 
learning correct exercise technique, they will perform 
baseline strength and physical function testing (day 4). 
They will also begin the 5-day loading protocol for supple-
mentation (outlined below) on day 4 in an effort to 
ensure intramuscular Cr stores are saturated prior to the 
beginning of the exercise programme. Further details on 
the familiarisation/testing phase are outlined in table 2.
Exercise programme
Participants assigned to each arm will attend a total of 
36 supervised exercise sessions for 12 weeks (thrice 
weekly, with a minimum 48 hours rest between sessions). 
Currently, the EMRI has four exercise clinics across Perth. 
Participants will be given the option to choose the clinic 
that is closest/most convenient for them to complete their 
training and all sessions will be supervised by an AEP. The 
resistance training programme will comprise eight exer-
cises targeting large muscle groups of the body (leg press, 
deadlift, step up, chest press, push-ups, shoulder press, 
lat pulldown and seated row). The initial loading will be 
equivalent to ~65% 1RM (3 sets of 12 reps), progressing 
towards ~80% 1RM (4 sets of 8 reps). Loading will be 
progressed throughout the programme using the ‘2 for 
2 rule’, whereby if a participant can complete two addi-
tional reps on the last set of an exercise for two consec-
utive sessions, the weight for an exercise (~5% to 10% 
for upper body; ~10% to 15% for lower body) will be 
increased. Concurrently, repetitions will gradually 
decrease across the programme to match the increase in 
weight. This type of resistance training protocol (ie, exer-
cises that stimulate large muscle groups, multiple sets and 
short rest) has been recommended to enhance the hyper-
trophic response to training.39 40 The programme will be 
autoregulated where variations in participants’ fatigue, 
recovery, energy and physical capacity will be used to 
adjust each training session. This model of autoregulation 
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Table 2 Familiarisation and testing phase
Week 1 familiarisation
Day 1 Day 2 Day 3
3-day food record
DXA
Questionnaires
2 sets x 8 reps (12RM) 2 sets x 10 reps (12RM)
Week 2 familiarisation and test
Day 4 Day 5 Day 6
1RM
Chest press, seated row, leg press
Physical function
400 m walk, TUG, repeated chair rise
Start loading protocol (4×5 g SUPP or PLA)
2 sets X 10 reps 2 sets X 12 reps
DXA, dual-energy X-ray absorptiometry; PLA, placebo; reps, repetitions; 1RM, one repetition maximum; SUPP, supplement; TUG, timed up 
and go.
Table 3 Outline of the 12-week exercise programme 
characteristics
Weeks Sets Reps Rest (seconds)
1–4 3 12 60
5–8 3 10 60
9–10 3 8 60
10–12 4 8 60
  Day 1 Day 2 Day 3
Exercise 
order
1.Deadlift 1.Push ups* 1.Deadlift
2.Leg press 2.Lat pulldown 2.Leg press
3.Push ups* 3.Chest press 3.Push ups*
4.Seated row 4.Seated row 4.Seated row
5.Step up 5.Shoulder 
press
5.Step up
6.Chest press 6.Deadlift 6.Chest press
7.Pulldown 7.Step up 7.Pulldown
8.Shoulder 
press
8.Leg press 8.Shoulder 
press
*Push-ups will be performed on a Smith machine, where 
the initial height of the bar will be adjusted to a point where 
individuals can perform 12 repetitions. The exercise will 
be progressed by lowering the bar (15 cm intervals) when 
participants can successfully complete all repetitions. When 
participants can complete all repetitions on the floor with good 
technique, they will be progressed to a free weight bench press 
movement.
has been previously proposed and currently being used in 
other exercise oncology trials. Moreover, any deviations 
to the protocol will be recorded in detail and reported in 
the final manuscript. Specific details of the programme 
are outlined in table 3.
Adherence
Adherence to the resistance training protocol will be 
reported as a function of how much of the programme 
was actually completed versus what was initially 
planned. Specifically, volume load (sets x reps x weight) 
will be used to calculate planned training volume for 
each session. The training volume that was actually 
completed will be recorded. Any modifications to the 
exercise programme will be made at the discretion of 
the AEPs supervising the exercise programme. How 
and why sessions were modified will be recorded and 
reported in the final manuscript. The adherence to exer-
cise will be reported as a ratio of completed to planned 
cumulative exercise, expressed as a percentage, previ-
ously outlined by Nilsen et al.41 Additionally, reasons for 
missing a session will also be reported, with resched-
uling of sessions permitted.
suPP and PLA protocol
Participants in the SUPP group will receive 20 g/day of 
Cr monohydrate for 5 days, beginning on day 4 of the 
familiarisation/testing phase (immediately after rando-
misation, approximately 7 days prior to first training 
session), divided into four equal doses throughout the 
day. Participants will then be given single daily doses of 
5 g for the duration of the 12-week training programme. 
This dosing protocol has been previously demonstrated 
to be safe and efficacious in older adults.18 22 25 27 Conse-
quently, the loading phase prior to the beginning of the 
resistance training programme was included to ensure 
intramuscular Cr stores were saturated prior to resistance 
training to ‘maximise’ the likelihood of seeing an effect 
of supplementation.20 Participants in the PLA group will 
follow the same dosing protocol with dextrose. Dextrose 
is inert in terms of training adaptations and has been 
used as PLA in prior supplementation trials.18 42 Partic-
ipants will be asked to dissolve the SUPPs in 200–300 
mL of juice (orange or apple) to mask the solubility 
of Cr and taste of dextrose. To increase compliance, 
participants will be asked to return empty packets to the 
research team once a week. SUPP packages will be coded 
so that neither the investigators nor the participants will 
be aware of contents.
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statistical analysis
To achieve 80% power at an alpha level of p<0.05 (two 
tailed), 25 participants per group would be required to 
detect a mean difference in change between the two 
groups for FFM of 1.4 kg at the end of the 12-week inter-
vention, based on our previous work in men receiving 
ADT11 and work by Brose et al18 investigating changes in 
body composition and muscle strength with Cr supple-
mentation and resistance training in older adults. To 
account for an attrition rate of ~10% seen in prior trials,7 43 
we aim to recruit 56 participants (SUPP n=28; PLA n=28). 
Statistical analysis will be conducted using SPSS (V.25, 
IBM). Normality of the distribution will be assessed using 
the Kolmogorov-Smirnov test. Summary descriptive statis-
tics will be used for participant characteristics. Baseline 
characteristics will be assessed using independent t-tests 
or the Mann-Whitney U test, as appropriate. Separate 
group (Condition: SUPP, PL) x time (baseline, follow-up) 
repeated-measures analyses of variance or analyses of 
covariance, where appropriate, will be performed for 
each endpoint. Any data not normally distributed will 
be log transformed (ln) for analysis. For categorical vari-
ables, Pearson X2 test will be used. Per-protocol analysis 
as well as an intention-to-treat approach with multiple 
imputations will be used to examine the data. Data will be 
deidentified and coded to classify which group the partic-
ipant is in, without any ability to identify the individual. 
Identifiable documents will be destroyed, with deidenti-
fied information kept in a password protected electronic 
folder only accessible to the study team.
Patient and public involvement
EMRI regularly communicates with consumer represen-
tatives (individuals with cancer and their caregivers) with 
an acute understanding of cancer treatment-related side 
effects and the broader experience to provide input into 
the study design to ensure research supports the needs 
of this patient population and the community at large. 
Community representatives will remain active in their 
involvement of this study through regular updates with 
members of the study team and will be encouraged to 
offer suggestions on how to develop materials for plain 
language summaries and dissemination. Further, the 
clinicians on the study (CIT and RC) have high PCa 
patient caseloads that allow them to discuss the design of 
trials to target interventions to the needs of their patients.
Ethics and dissemination
Any protocol amendments will be submitted to the 
ethics committee for approval and these changes will 
be reflected in the trial registration. If the results of this 
trial demonstrate that Cr supplementation can augment 
adaptations of body composition, physical function and/
or psychosocial outcomes to resistance training, this study 
will provide effect sizes that will inform the design of subse-
quent definitive randomised controlled trials. The results 
of this study will be published in peer-reviewed journals 
and presented at various national and international 
conferences. The results of the trial will also be presented 
to all study participants (individually and collectively), 
and the EMRI team will work with local community 
members and support groups to develop materials for 
plain language summaries and dissemination.
dIsCussIon
Despite well-documented clinical benefits as a PCa treat-
ment, ADT is consistently associated with profound 
worsening of muscle mass, neuromuscular strength and 
physical function in men with PCa.2–5It has been postu-
lated that reductions in muscle strength and physical func-
tion contribute to the cascade of physiological decline in 
men with PCa receiving ADT, ultimately resulting in a 
disability condition.6 44 This contributes to a decline in 
activities of daily living, social activities and QOL.6 44 As 
a result, men with PCa are at a heightened risk of frailty, 
falls and fractures, and early mortality.3 5 6 Further, the 
decline in body composition is also associated with sarco-
penic obesity, leading to increases in cardiometabolic risk 
factors.45 46 Consequently, investigations into strategies 
that may improve musculoskeletal health is of critical 
importance in this population.
An ever-increasing body of literature supports the bene-
fits of exercise, in particular resistance training, to coun-
teract the loss of muscle mass and strength in men with 
PCa receiving ADT.9 10 44 47 Recently, trials have emerged 
examining the potential for nutritional supplementa-
tion to augment adaptations to resistance training in 
men with PCa receiving ADT.48–50 Cr is one of the most 
widely studied SUPPs, with increasing application across a 
breadth of populations.17 51–58 Of particular relevance, Cr 
supplementation has been consistently demonstrated to 
enhance FFM in vulnerable populations that experience 
similar issues with loss of muscle mass to PCa, such as HIV, 
muscular dystrophy and older adults.23–30 Results from a 
recent meta-analysis by Chilibeck et al59 demonstrate that 
Cr supplementation, in addition to resistance training, can 
result in ~1.4 kg greater increase in FFM compared with 
resistance training alone in older adults. The authors also 
reported that Cr supplementation, in addition to resis-
tance training, resulted in a greater increase in upper and 
lower body strength.59 Given the consistent reduction in 
FFM, muscle strength and physical function in men with 
PCa receiving ADT, particularly compared with appar-
ently healthy controls, these results highlight the consid-
erable therapeutic potential of Cr supplementation to 
more effectively ameliorate treatment-related side effects 
in this population. The safety of Cr is well established in a 
variety of apparently healthy and clinical populations, yet 
no research to date has investigated Cr supplementation 
in individuals with cancer.16 Consequently, the inclusion 
of questions on gastrointestinal distress and creatinine 
as a marker of kidney function will provide invaluable 
insight into the potential (or lack thereof) side effects of 
Cr supplementation in this population.
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LIMItAtIons
Several limitations of the study warrant discussion. The 
study is investigating Cr supplementation in individuals 
with PCa undergoing ADT, thus generalisability to other 
cancer populations is limited.18 Though a follow-up 
period to analyse the sustainability of outcomes would 
certainly be advantageous, limitations in funding and 
resources make it difficult to undertake in this study. As 
such the longer term benefits will not be elucidated.
ConCLusIon
This study will be the first specifically designed to investi-
gate the efficacy of combining resistance training and Cr 
supplementation on FFM, muscle strength and physical 
function in men with PCa receiving ADT. Should the find-
ings from the proposed study support the preliminary 
efficacy of Cr supplementation, appropriate effect sizes 
can be determined to help with the design of randomised 
controlled trials using Cr to target muscle loss in PCa.
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